ARS Pharmaceuticals, Inc.

NasdaqGM:SPRY Stock Report

Market Cap: US$1.1b

ARS Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:SPRY Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
30 Jul 25SellUS$18,642,626Deerfield Management Company, L.P.Company1,023,320US$18.36
21 Jul 25SellUS$18,578,437Deerfield Management Company, L.P.Company1,090,971US$18.12
27 Jun 25SellUS$13,663,151Deerfield Management Company, L.P.Company740,149US$18.46
20 May 25SellUS$41,853Alexander FitzpatrickIndividual2,969US$14.10
27 Nov 24SellUS$1,411,742Justin ChakmaIndividual100,000US$14.39
12 Nov 24SellUS$10,143,706Deerfield Management Company, L.P.Company563,270US$18.15

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of SPRY?
Owner TypeNumber of SharesOwnership Percentage
Hedge Funds7,610,2177.31%
Individual Insiders9,868,9649.48%
Private Companies10,106,6479.71%
VC/PE Firms19,149,48718.4%
Institutions57,380,15955.1%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 84.85% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11%
RA Capital Management, L.P.
10,860,977US$118.2m0%1.6%
10.2%
The Lowenthal-Tanimoto Family Trust
10,106,647US$110.0m267%no data
8.39%
OrbiMed Advisors LLC
8,288,510US$90.2m0%1.46%
7.7%
Deerfield Management Company, L.P.
7,610,217US$82.8m-21.7%1.56%
4.88%
Pratik Shah
4,824,554US$52.5m0%no data
4.48%
BlackRock, Inc.
4,423,464US$48.1m2.9%no data
4.06%
SR One Capital Management, LP
4,012,903US$43.7m0%7.99%
3.87%
AllianceBernstein L.P.
3,825,793US$41.6m-2.47%0.01%
3.32%
Sarina Tanimoto
3,276,854US$35.7m0%no data
3.3%
The Vanguard Group, Inc.
3,262,673US$35.5m-6.47%no data
2.27%
Citadel Advisors LLC
2,242,176US$24.4m180%0.02%
2.22%
State Street Global Advisors, Inc.
2,194,493US$23.9m8.04%no data
1.85%
Franklin Resources, Inc.
1,828,501US$19.9m-1.55%0.01%
1.75%
Adage Capital Management, L.P.
1,728,000US$18.8m0%0.03%
1.73%
Southpoint Capital Advisors LP
1,709,069US$18.6m0%0.44%
1.59%
FMR LLC
1,566,997US$17.0m58.2%no data
1.52%
Aberdeen Group Plc
1,502,575US$16.3m49.9%0.01%
1.45%
Wellington Management Group LLP
1,433,187US$15.6m988%no data
1.39%
Medical Strategy GmbH, Asset Management Arm
1,369,466US$14.9m0%1.04%
1.37%
Octagon Capital Advisors LP
1,350,000US$14.7m116%2.39%
1.36%
Geode Capital Management, LLC
1,342,387US$14.6m6.5%no data
1.32%
MPM BioImpact LLC
1,303,399US$14.2m-0.74%2.17%
1.31%
Goldman Sachs Group, Investment Banking and Securities Investments
1,296,538US$14.1m118%0.01%
1.31%
Rubric Capital Management LP
1,294,878US$14.1m25.8%0.21%
1.21%
Richard Lowenthal
1,196,494US$13.0m-77.7%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/04 01:30
End of Day Share Price 2025/09/03 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ARS Pharmaceuticals, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joshua SchimmerCantor Fitzgerald & Co.
Roanna Clarissa RuizLeerink Partners LLC
Andreas ArgyridesOppenheimer & Co. Inc.